The Final Act for Autoimmune Disease
What if autoimmune diseases could be cured with a one-time treatment? At Cabaletta Bio, we believe it is possible.
On a proven foundation of CAR T technology and an established track record of clinical operational excellence in cell therapy in autoimmunity, we are developing innovative engineered T cell therapies for patients with autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA™) platform is designed to provide deep, durable, and potentially curative responses with one-time administration, with the possibility of eliminating the need for chronic immune suppressive therapies. The CABA™ platform has potential applicability across many B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, systemic sclerosis, pemphigus vulgaris and myasthenia gravis, and it encompasses two approaches.
The Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach is designed to enable transient eradication of all B cells in patients with autoimmune diseases driven by B cells, with subsequent repopulation of normal B cells, thus resetting the immune system and restoring immune health. Our lead CARTA candidate, CABA-201, is being developed in autoimmune diseases with high unmet need.
Cabaletta’s proprietary Chimeric AutoAntibody Receptor T (CAART) cell approach is designed for diseases driven by specific autoantibodies, to enable permanent elimination of only disease-causing B cells with preservation of the healthy immune system. Our most advanced CAART candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ trial, which is a Phase 1 study for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV). The MusCAARTes™ trial for our MuSK-CAART candidate in MuSK-associated myasthenia gravis is progressing into a Phase 1 clinical trial, and we have advanced several other high-priority targets into discovery and preclinical testing.
To harness the immune system through innovative cell and gene therapies to deliver accessible cures for patients.